Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection.

Kloprogge F, Hammond R, Kipper K, Gillespie SH, Della Pasqua O.

Sci Rep. 2019 Sep 13;9(1):13228. doi: 10.1038/s41598-019-49556-5.

2.

Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

Kloprogge F, Hammond R, Copas A, Gillespie SH, Della Pasqua O.

J Antimicrob Chemother. 2019 Aug 25. pii: dkz369. doi: 10.1093/jac/dkz369. [Epub ahead of print]

PMID:
31504558
3.

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.

Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Gillespie SH.

BMC Pulm Med. 2019 Aug 14;19(1):152. doi: 10.1186/s12890-019-0907-6.

4.

Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture.

Svensson RJ, Sabiiti W, Kibiki GS, Ntinginya NE, Bhatt N, Davies G, Gillespie SH, Simonsson USH.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00652-19. doi: 10.1128/AAC.00652-19. Print 2019 Oct.

PMID:
31358585
5.

Molecular Bacterial Load Assay Concurs with Culture on NaOH-Induced Loss of Mycobacterium tuberculosis Viability.

Mtafya B, Sabiiti W, Sabi I, John J, Sichone E, Ntinginya NE, Gillespie SH.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e01992-18. doi: 10.1128/JCM.01992-18. Print 2019 Jul.

PMID:
31018981
6.

Heat Inactivation Renders Sputum Safe and Preserves Mycobacterium tuberculosis RNA for Downstream Molecular Tests.

Sabiiti W, Azam K, Esmeraldo E, Bhatt N, Rachow A, Gillespie SH.

J Clin Microbiol. 2019 Mar 28;57(4). pii: e01778-18. doi: 10.1128/JCM.01778-18. Print 2019 Apr.

7.

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study.

Murphy ME, Wills GH, Murthy S, Louw C, Bateson ALC, Hunt RD, McHugh TD, Nunn AJ, Meredith SK, Mendel CM, Spigelman M, Crook AM, Gillespie SH; REMoxTB consortium.

BMC Med. 2018 Oct 17;16(1):189. doi: 10.1186/s12916-018-1169-5.

8.

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy.

Ahmed MIM, Ntinginya NE, Kibiki G, Mtafya BA, Semvua H, Mpagama S, Mtabho C, Saathoff E, Held K, Loose R, Kroidl I, Chachage M, von Both U, Haule A, Mekota AM, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N, Geldmacher C.

Front Immunol. 2018 Sep 28;9:2247. doi: 10.3389/fimmu.2018.02247. eCollection 2018.

9.

Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis.

Kennedy JA, Baron VO, Hammond RJH, Sloan DJ, Gillespie SH.

Tuberculosis (Edinb). 2018 Sep;112:79-82. doi: 10.1016/j.tube.2018.07.008. Epub 2018 Aug 1.

PMID:
30205972
10.

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH.

BMC Infect Dis. 2018 Jul 11;18(1):317. doi: 10.1186/s12879-018-3230-6.

11.

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R.

Clin Infect Dis. 2018 Jun 18;67(1):34-41. doi: 10.1093/cid/ciy026.

12.

The impact of repeated NALC/NaOH- decontamination on the performance of Xpert MTB/RIF assay.

Rachow A, Saathoff E, Mtafya B, Mapamba D, Mangu C, Rojas-Ponce G, Ntinginya NE, Boeree M, Heinrich N, Gillespie SH, Hoelscher M; PanACEA-Consortium.

Tuberculosis (Edinb). 2018 May;110:56-58. doi: 10.1016/j.tube.2018.04.001. Epub 2018 Apr 5.

PMID:
29779774
13.

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

Murthy SE, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy ME, Murray SR, Nunn AJ, Phillips PPJ, Singh KP, McHugh TD, Gillespie SH; REMoxTB Consortium.

BMC Med. 2018 May 21;16(1):73. doi: 10.1186/s12916-018-1053-3.

14.

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations.

Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Moodley M, Boeree MJ, Simonsson USH.

J Infect Dis. 2018 Aug 14;218(6):991-999. doi: 10.1093/infdis/jiy242.

PMID:
29718390
15.

Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin.

Wicha SG, Clewe O, Svensson RJ, Gillespie SH, Hu Y, Coates ARM, Simonsson USH.

Clin Pharmacol Ther. 2018 Dec;104(6):1208-1218. doi: 10.1002/cpt.1102. Epub 2018 Jun 19.

16.

Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.

Liu Y, Pertinez H, Davies GR, Gillespie SH, Coates AR, Hu Y.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00190-18. doi: 10.1128/AAC.00190-18. Print 2018 Jul.

17.

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D.

Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X. Erratum in: Lancet Respir Med. 2018 Apr 18;:.

PMID:
29595509
18.

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH.

BMC Med. 2018 Mar 28;16(1):46. doi: 10.1186/s12916-018-1033-7.

19.

Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model.

Bowness R, Chaplain MAJ, Powathil GG, Gillespie SH.

J Theor Biol. 2018 Jun 7;446:87-100. doi: 10.1016/j.jtbi.2018.03.006. Epub 2018 Mar 7.

20.

OMNIgene.SPUTUM suppresses contaminants while maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport.

Azam K, Cadir N, Madeira C, Gillespie SH, Sabiiti W.

ERJ Open Res. 2018 Feb 16;4(1). pii: 00074-2017. doi: 10.1183/23120541.00074-2017. eCollection 2018 Jan.

21.

Using RT qPCR for Quantifying Mycobacteria marinum from In Vitro and In Vivo Samples.

Xaio H, Gillespie SH.

Methods Mol Biol. 2018;1736:137-145. doi: 10.1007/978-1-4939-7638-6_13.

PMID:
29322466
22.

Enhanced Methodologies for Detecting Phenotypic Resistance in Mycobacteria.

Hammond RJH, Baron VO, Lipworth S, Gillespie SH.

Methods Mol Biol. 2018;1736:85-94. doi: 10.1007/978-1-4939-7638-6_8.

PMID:
29322461
23.

Detecting Phenotypically Resistant Mycobacterium tuberculosis Using Wavelength Modulated Raman Spectroscopy.

Baron VO, Chen M, Clark SO, Williams A, Dholakia K, Gillespie SH.

Methods Mol Biol. 2018;1736:41-50. doi: 10.1007/978-1-4939-7638-6_4.

PMID:
29322457
24.

A spatially heterogeneous network-based metapopulation software model applied to the simulation of a pulmonary tuberculosis infection.

Pitcher MJ, Bowness R, Dobson S, Gillespie SH.

Appl Netw Sci. 2018;3(1):33. doi: 10.1007/s41109-018-0091-2. Epub 2018 Aug 23.

25.

Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing.

Parcell BJ, Oravcova K, Pinheiro M, Holden MTG, Phillips G, Turton JF, Gillespie SH.

J Hosp Infect. 2018 Mar;98(3):282-288. doi: 10.1016/j.jhin.2017.12.005. Epub 2017 Dec 8.

26.

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

Phillips PPJ, Mendel CM, Nunn AJ, McHugh TD, Crook AM, Hunt R, Bateson A, Gillespie SH.

BMC Med. 2017 Nov 24;15(1):207. doi: 10.1186/s12916-017-0955-9.

27.

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

Murphy ME, Phillips PPJ, Mendel CM, Bongard E, Bateson ALC, Hunt R, Murthy S, Singh KP, Brown M, Crook AM, Nunn AJ, Meredith SK, Lipman M, McHugh TD, Gillespie SH; REMoxTB Consortium.

BMC Med. 2017 Oct 27;15(1):192. doi: 10.1186/s12916-017-0947-9.

28.

Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease.

Baron VO, Chen M, Clark SO, Williams A, Hammond RJH, Dholakia K, Gillespie SH.

Sci Rep. 2017 Aug 29;7(1):9844. doi: 10.1038/s41598-017-10234-z.

29.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

30.

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.

Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH.

Clin Pharmacol Ther. 2018 Apr;103(4):674-683. doi: 10.1002/cpt.778. Epub 2017 Aug 7.

31.

Mycobacterial Load Assay.

Gillespie SH, Sabiiti W, Oravcova K.

Methods Mol Biol. 2017;1616:89-105. doi: 10.1007/978-1-4939-7037-7_5.

PMID:
28600763
32.

Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.

Svensson RJ, Gillespie SH, Simonsson USH.

J Antimicrob Chemother. 2017 Aug 1;72(8):2311-2319. doi: 10.1093/jac/dkx129.

33.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

34.

The implications of model-informed drug discovery and development for tuberculosis.

Muliaditan M, Davies GR, Simonsson USH, Gillespie SH, Della Pasqua O.

Drug Discov Today. 2017 Mar;22(3):481-486. doi: 10.1016/j.drudis.2016.09.004. Epub 2016 Sep 28.

PMID:
27693714
35.

Defining dormancy in mycobacterial disease.

Lipworth S, Hammond RJ, Baron VO, Hu Y, Coates A, Gillespie SH.

Tuberculosis (Edinb). 2016 Jul;99:131-42. doi: 10.1016/j.tube.2016.05.006. Epub 2016 May 28. Review.

PMID:
27450015
36.

Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings.

Sabiiti W, Mtafya B, Kuchaka D, Azam K, Viegas S, Mdolo A, Farmer EC, Khonga M, Evangelopoulos D, Honeyborne I, Rachow A, Heinrich N, Ntinginya NE, Bhatt N, Davies GR, Jani IV, McHugh TD, Kibiki G, Hoelscher M, Gillespie SH; PANBIOME (Pan-African Biomarker Expansion Programme) consortium.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1004-9. doi: 10.5588/ijtld.15.0951.

PMID:
27393531
37.

Therapy for Tuberculous Meningitis.

Boeree MJ, Gillespie SH, Hoelscher M; PanACEA core team.

N Engl J Med. 2016 Jun 2;374(22):2187-8. doi: 10.1056/NEJMc1602291. No abstract available.

PMID:
27248636
38.

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy.

Honeyborne I, McHugh TD, Kuittinen I, Cichonska A, Evangelopoulos D, Ronacher K, van Helden PD, Gillespie SH, Fernandez-Reyes D, Walzl G, Rousu J, Butcher PD, Waddell SJ.

BMC Med. 2016 Apr 7;14:68. doi: 10.1186/s12916-016-0609-3.

39.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M.

BMC Med. 2016 Mar 23;14:51. doi: 10.1186/s12916-016-0597-3.

40.

The role of moxifloxacin in tuberculosis therapy.

Gillespie SH.

Eur Respir Rev. 2016 Mar;25(139):19-28. doi: 10.1183/16000617.0085-2015. Review.

41.

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH.

BMC Med. 2016 Feb 23;14:36. doi: 10.1186/s12916-016-0585-7. No abstract available.

42.

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH.

BMC Med. 2016 Feb 4;14:19. doi: 10.1186/s12916-016-0565-y. Erratum in: BMC Med. 2016;14:36. Crook, Angela [corrected to Crook, Angela M].

43.

A Step toward an Optimized Rifampin Dose Completed.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):525-6. doi: 10.1164/rccm.201506-1061LE. No abstract available.

PMID:
26278799
44.

Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?

Hammond RJ, Baron VO, Oravcova K, Lipworth S, Gillespie SH.

J Antimicrob Chemother. 2015 Oct;70(10):2823-7. doi: 10.1093/jac/dkv178. Epub 2015 Jul 9.

PMID:
26163401
45.

Effective anti-tuberculosis therapy correlates with plasma small RNA.

Honeyborne I, Lipman MC, Eckold C, Evangelopoulos D, Gillespie SH, Pym A, McHugh TD.

Eur Respir J. 2015 Jun;45(6):1741-4. doi: 10.1183/09031936.00221214. Epub 2015 Mar 5. No abstract available.

46.

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium.

Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65. doi: 10.1164/rccm.201407-1264OC.

PMID:
25654354
47.

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.

Gillespie SH, Mendel CM; REMoxTB Consortium.

N Engl J Med. 2015 Feb 5;372(6):577. doi: 10.1056/NEJMc1414718. No abstract available.

PMID:
25651256
48.

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.

Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH; Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA); Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA.

J Antimicrob Chemother. 2015 May;70(5):1558-66. doi: 10.1093/jac/dku553. Epub 2015 Jan 27.

PMID:
25630641
49.

HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target.

Hu Y, Liu A, Menendez MC, Garcia MJ, Oravcova K, Gillespie SH, Davies GR, Mitchison DA, Coates AR.

Tuberculosis (Edinb). 2015 Jan;95(1):31-6. doi: 10.1016/j.tube.2014.11.002. Epub 2014 Nov 20.

PMID:
25481272
50.

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.

Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH.

J Antimicrob Chemother. 2015 Feb;70(2):448-55. doi: 10.1093/jac/dku415. Epub 2014 Oct 25.

PMID:
25344806

Supplemental Content

Loading ...
Support Center